Preoperative and pre-chemotherapy CA-125 levels in high-risk early-stage ovarian cancer - An NRG/GOG study
CONCLUSIONS: Preoperative CA-125 was elevated in nearly 80% of high-risk early-stage ovarian cancer patients. Pre-chemotherapy CA-125 was associated with recurrence-free and overall survival; however, preoperative CA-125 was not prognostic.PMID:38134754 | DOI:10.1016/j.ygyno.2023.12.009 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 22, 2023 Category: Cancer & Oncology Authors: John K Chan Chunqiao Tian Joshua P Kesterson Ken Y Lin Kathleen Darcy Michael T Richardson Daniel S Kapp Bradley J Monk Leah McNally Lisa Landrum Larry Copeland Joan L Walker Robert M Wenham Neil Phippen Nick M Spirtos Krishnansu Tewari Mark Shahin Laurel Source Type: research
The role of obesity in treatment planning for early-stage cervical cancer
CONCLUSION: In this cohort of RH-eligible cervical cancer patients, BMI was independently associated with disposition to RT. Studies demonstrate that RH is feasible and safe in obese patients with no difference in RFS or OS when compared to non-obese patients. Thus, the decision for disposition to RT should not be based on obesity alone.PMID:38134755 | DOI:10.1016/j.ygyno.2023.12.006 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 22, 2023 Category: Cancer & Oncology Authors: Taylor A Rives Taylor J Orellana Brigid S Mumford Paniti Sukumvanich Madeleine Courtney-Brooks Jessica Berger Jason Conger John A Vargo Sushil Beriwal Jamie Lesnock Li Wang Brian C Orr Sarah E Taylor Source Type: research
Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis
CONCLUSIONS: Pretreatment systemic inflammatory markers are associated with survival outcomes in patients with EC, with the HALP score being a prognostic factor for PFS and OS.PMID:38113633 | DOI:10.1016/j.ygyno.2023.12.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 19, 2023 Category: Cancer & Oncology Authors: Shin Nishio Kenta Murotani Wataru Yamagami Shiro Suzuki Hidekatsu Nakai Kazuyoshi Kato Hideki Tokunaga Hiroyuki Nomura Yoshihito Yokoyama Kazuhiro Takehara Aikou Okamoto Source Type: research
Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis
CONCLUSIONS: Pretreatment systemic inflammatory markers are associated with survival outcomes in patients with EC, with the HALP score being a prognostic factor for PFS and OS.PMID:38113633 | DOI:10.1016/j.ygyno.2023.12.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 19, 2023 Category: Cancer & Oncology Authors: Shin Nishio Kenta Murotani Wataru Yamagami Shiro Suzuki Hidekatsu Nakai Kazuyoshi Kato Hideki Tokunaga Hiroyuki Nomura Yoshihito Yokoyama Kazuhiro Takehara Aikou Okamoto Source Type: research
Pretreatment systemic inflammatory markers predict survival in endometrial cancer: A Japanese Gynecologic Oncology Group 2043 exploratory data analysis
CONCLUSIONS: Pretreatment systemic inflammatory markers are associated with survival outcomes in patients with EC, with the HALP score being a prognostic factor for PFS and OS.PMID:38113633 | DOI:10.1016/j.ygyno.2023.12.007 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 19, 2023 Category: Cancer & Oncology Authors: Shin Nishio Kenta Murotani Wataru Yamagami Shiro Suzuki Hidekatsu Nakai Kazuyoshi Kato Hideki Tokunaga Hiroyuki Nomura Yoshihito Yokoyama Kazuhiro Takehara Aikou Okamoto Source Type: research
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs
CONCLUSIONS: As MOGCTs affect women of child-bearing age, fertility preservation represents a major treatment issue. Our results are consistent with the available evidence, confirming that adjuvant chemotherapy for MOGCT does not impact the reproductive function and fertility.PMID:38104526 | DOI:10.1016/j.ygyno.2023.11.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 17, 2023 Category: Cancer & Oncology Authors: Francesca M Vasta Gennaro Cormio Chiara Cassani Alice Bergamini Giovanna Scarfone Gabriella Ferrandina Rocco De Vivo Marco Marinaccio Saverio Danese Francesco Raspagliesi Sandro Pignata Giorgia Mangili Source Type: research
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer
CONCLUSION: Advanced EOC patients with BRCA1/2 mutations exhibited no significant difference in OS between olaparib and niraparib, indicating the need to consider individualized strategies for selecting PARP inhibitors based on adverse event profiles.PMID:38104527 | DOI:10.1016/j.ygyno.2023.11.037 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 17, 2023 Category: Cancer & Oncology Authors: Ji Hyun Kim Se Ik Kim Eun Young Park Eun Taeg Kim Hyesu Kim Sangeon Kim Sang-Yoon Park Myong Cheol Lim Source Type: research
Eugen Bogdan Aburel, a pioneer of fertility sparing surgery
Gynecol Oncol. 2023 Dec 16;181:40-45. doi: 10.1016/j.ygyno.2023.10.024. Online ahead of print.ABSTRACTEugen Bogdan Aburel was pioneer of the fertility sparing surgery in early cervical cancer in young women desiring to preserve their childbearing potential. He graduated in Romania but started specializing in obstetrics and gynecology in Paris, where he had the chance to work with the most prominent professors of the time and do research at Sorbonne, the most famous French higher education institution. Most of his discoveries date from the time he spent in Paris hospitals, proving that a good medical school can generate rem...
Source: Gynecologic Oncology - December 17, 2023 Category: Cancer & Oncology Authors: Gheorghe Peltecu Source Type: research
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs
CONCLUSIONS: As MOGCTs affect women of child-bearing age, fertility preservation represents a major treatment issue. Our results are consistent with the available evidence, confirming that adjuvant chemotherapy for MOGCT does not impact the reproductive function and fertility.PMID:38104526 | DOI:10.1016/j.ygyno.2023.11.023 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 17, 2023 Category: Cancer & Oncology Authors: Francesca M Vasta Gennaro Cormio Chiara Cassani Alice Bergamini Giovanna Scarfone Gabriella Ferrandina Rocco De Vivo Marco Marinaccio Saverio Danese Francesco Raspagliesi Sandro Pignata Giorgia Mangili Source Type: research
Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer
CONCLUSION: Advanced EOC patients with BRCA1/2 mutations exhibited no significant difference in OS between olaparib and niraparib, indicating the need to consider individualized strategies for selecting PARP inhibitors based on adverse event profiles.PMID:38104527 | DOI:10.1016/j.ygyno.2023.11.037 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 17, 2023 Category: Cancer & Oncology Authors: Ji Hyun Kim Se Ik Kim Eun Young Park Eun Taeg Kim Hyesu Kim Sangeon Kim Sang-Yoon Park Myong Cheol Lim Source Type: research
Eugen Bogdan Aburel, a pioneer of fertility sparing surgery
Gynecol Oncol. 2023 Dec 16;181:40-45. doi: 10.1016/j.ygyno.2023.10.024. Online ahead of print.ABSTRACTEugen Bogdan Aburel was pioneer of the fertility sparing surgery in early cervical cancer in young women desiring to preserve their childbearing potential. He graduated in Romania but started specializing in obstetrics and gynecology in Paris, where he had the chance to work with the most prominent professors of the time and do research at Sorbonne, the most famous French higher education institution. Most of his discoveries date from the time he spent in Paris hospitals, proving that a good medical school can generate rem...
Source: Gynecologic Oncology - December 17, 2023 Category: Cancer & Oncology Authors: Gheorghe Peltecu Source Type: research
Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study
CONCLUSIONS: Higher than normal BMI was associated with higher incidence rates of cervical cancer and lower rates of precancer detection, emphasizing the importance of further research in possible mechanisms behind this association.PMID:38103421 | DOI:10.1016/j.ygyno.2023.12.002 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 16, 2023 Category: Cancer & Oncology Authors: Aivara Urbute Kirsten Frederiksen Louise T Thomsen Ulrik Schi øler Kesmodel Susanne K Kjaer Source Type: research
Optimising endometrial cancer survivorship through lifestyle change
Gynecol Oncol. 2023 Dec;179:A1-A2. doi: 10.1016/j.ygyno.2023.11.032.NO ABSTRACTPMID:38103916 | DOI:10.1016/j.ygyno.2023.11.032 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 16, 2023 Category: Cancer & Oncology Authors: S J Kitson E J Crosbie Source Type: research
Overweight and obesity as risk factors for cervical cancer and detection of precancers among screened women: A nationwide, population-based cohort study
CONCLUSIONS: Higher than normal BMI was associated with higher incidence rates of cervical cancer and lower rates of precancer detection, emphasizing the importance of further research in possible mechanisms behind this association.PMID:38103421 | DOI:10.1016/j.ygyno.2023.12.002 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 16, 2023 Category: Cancer & Oncology Authors: Aivara Urbute Kirsten Frederiksen Louise T Thomsen Ulrik Schi øler Kesmodel Susanne K Kjaer Source Type: research
Optimising endometrial cancer survivorship through lifestyle change
Gynecol Oncol. 2023 Dec;179:A1-A2. doi: 10.1016/j.ygyno.2023.11.032.NO ABSTRACTPMID:38103916 | DOI:10.1016/j.ygyno.2023.11.032 (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - December 16, 2023 Category: Cancer & Oncology Authors: S J Kitson E J Crosbie Source Type: research
